PDCD1 and metastatic melanoma: Dual checkpoint inhibition with CTLA-4 and PD-1 inhibitors has become a well-established therapeutic option for metastatic melanoma with long-term outcomes, yet at the expense of toxicity with more than half of patients receiving ipilimumab and nivolumab having grade 3 or 4 adverse events.